![](/rp/kFAqShRrnkQMbH6NYLBYoJ3lq9s.png)
Medicines - Gilead Sciences
Access the list of approved Gilead therapies across virology including HIV, liver disease including hepatitis and primary biliary cholangitis, oncology & inflammation.
Gilead Sciences
2010年2月5日 · As the long-standing leader in HIV, we’re committed to helping end the epidemic with the advancement of unprecedented long-acting medications for both HIV prevention and …
Virology, Inflammation, & Oncology Pipeline | Gilead
2024年11月6日 · Through science and innovative partnerships, Gilead expands research and development programs in virology, oncology, & inflammation. Learn about our pipeline.
Our Medications │ Gilead Medical Information
This site is an online medical resource that provides access to scientific information about Gilead products and related information. The information provided is not intended to be and should …
Gilead Sciences Beats Q4 EPS Forecast | The Motley Fool
18 小时之前 · Key success factors for Gilead Sciences include continued innovation and successful commercialization of new products like lenacapavir, an HIV pre-exposure …
Gilead Sciences - Wikipedia
Gilead Sciences, Inc. (/ ˈ ɡ ɪ l i ə d /) is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the …
Home │ Gilead Medical Information
Committed to improving the lives of patients, Gilead Medical Information strives to equip US healthcare professionals with scientific and clinical information about our products. Search our …
Home │ Gilead Medical Information
Search for easy-to-access information on Gilead medicines. Use the call, inquire, and chat functions to connect with a Gilead Medical representative.
Our Therapeutic Areas - Gilead
For over 35 years, Gilead has discovered, developed and delivered innovative therapies in areas of great unmet need. We helped transform HIV from a fatal disease to one that can be well …
2025 GILEAD and LEO PHARMA enters into strategic partnership
2025年1月11日 · Under this partnership, Gilead will acquire LEO Pharma’s comprehensive preclinical oral STAT6 small molecule inhibitors and targeted protein degraders. Gilead will …
- 某些结果已被删除